SARS-CoV-2 infection among patients with systemic autoimmune diseases

https://doi.org/10.1016/j.autrev.2020.102575Get rights and content

Highlights

  • Patients with systemic autoimmune diseases usually carry an increased risk of infections

  • Data on the occurrence of SARS-CoV-2 infection in these patients are scarce

  • We evaluated SARS-CoV-2 infection among 458 patients with systemic autoimmune diseases

  • The occurrence of the infection was similar to that observed in the general population

  • Patients with autoimmune diseases do not seem be at higher risk of SARS-CoV-2 infection

Abstract

Objectives

This study aimed to evaluate the prevalence of clinically overt SARS-CoV-2 infection (COVID-19) among patients with systemic autoimmune diseases residing in Tuscany, and to compare it with that observed in the general Tuscan population.

Methods

In this cross-sectional study, Tuscan outpatients with systemic autoimmune diseases followed at a tertiary referral centre were telephonically interviewed between April 1st-14th 2020 to collect demographic and clinical data, information on ongoing immunomodulating/immunosuppressive treatments, and on the presence of symptoms suspected of SARS-CoV-2 or of a confirmed infection.

Results

458 patients were interviewed [74% female, median age 56 years (IQR 43–68)]; 56% of them were receiving corticosteroids, 44% traditional disease-modifying anti-rheumatic drugs (DMARDs), of whom 23% hydroxychloroquine, 5% colchicine, while 41% were on biologic DMARDs (of whom 9% on tocilizumab). Thirteen patients reported symptoms suggesting SARS-CoV-2 infection. Of them, 7 had undergone nasopharyngeal swab and only one was positive and developed severe SARS-CoV-2 complications. Within our cohort, the prevalence of SARS-CoV-2 infection was therefore 0.22% (0.01–1.21%), comparable to that observed in the general population of Tuscany [0.20% (0.20–0.21%), p = .597].

Conclusions

Patients with systemic autoimmune diseases do not seem to carry an increased risk of SARS- CoV-2 infection as compared to the general population.

Keywords

COVID-19
Systemic autoimmune diseases
Immunosuppressants
Hydroxychloroquine
Tocilizumab

Cited by (0)

1

equal contribution.

View Abstract